好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Early Recanalization and Distal Thrombus Migration in Large Vessel Occlusion Stroke Undergoing Bridging Thrombolysis with Alteplase Versus Tenecteplase
Cerebrovascular Disease and Interventional Neurology
S22 - Innovations in Cerebrovascular Therapy (5:18 PM-5:30 PM)
010

Bridging thrombolysis can facilitate early recanalization in LVOS, potentially reducing the need for EVT. The relative efficacy of TPA versus TNK in achieving complete versus partial clot dissolution and its influence on subsequent EVT requires further investigation.

To compare early recanalization outcomes in large vessel occlusion stroke (LVOS) patients receiving thrombolysis with alteplase (TPA) versus tenecteplase (TNK) prior to endovascular treatment (EVT).

This retrospective review included 280 consecutive LVOS patients treated with intravenous thrombolysis (TPA or TNK) and referred for EVT between January 2020 and May 2024. Early recanalization endpoints were defined as: (1) neurological improvement precluding EVT, (2) eTICI 2b-3 on cerebral angiography, and (3) distal thrombus migration compared to initial CT angiography, with or without the need for mechanical thrombectomy.

Of the 280 patients, 181 received TNK (64.6%) and 99 received TPA (35.4%). The most common occlusion sites were the M1 segment of the middle cerebral artery (46.4%), M2 segment (24.3%), and tandem ICA/MCA occlusion (15.7%). Any recanalization endpoint was achieved in 42/181 TNK cases (23.2%) versus 11/99 TPA cases (11.1%) (p=0.016). Neurological improvement precluded EVT in 4.4% of TNK cases versus 3.0% of TPA cases (p=0.752). First-pass angiography showed eTICI 2b-3, leading to procedure termination in 7.7% of TNK and 6.1% of TPA cases (p=0.603). First-pass angiography also demonstrated partial recanalization and a need for mechanical thrombectomy in 11% of TNK and 2% of TPA cases (p=0.009). Overall, partial recanalization occurred in 17.3% of TNK cases versus 7.3% of TPA cases (p=0.026). Multivariable analysis identified lower baseline NIHSS and TNK administration as independent predictors of early recanalization.

In LVOS patients, thrombolysis with tenecteplase is associated with higher rates of early recanalization compared to alteplase, primarily due to partial recanalization and distal thrombus migration.

Authors/Disclosures
Grant N. Badger
PRESENTER
Mr. Badger has nothing to disclose.
Tyler M. Bielinski Mr. Bielinski has nothing to disclose.
Veronica Bohl Ms. Bohl has nothing to disclose.
Kelsey Kline, BS Miss Kline has nothing to disclose.
Prateeka Koul, MD Dr. Koul has nothing to disclose.
Anthony Noto, MD (Geisinger Medical Center) Dr. Noto has nothing to disclose.
Clemens M. Schirmer, MD, PhD Dr. Schirmer has received personal compensation for serving as an employee of Geisinger. Dr. Schirmer has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Balt. Dr. Schirmer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Medtronic. Dr. Schirmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stryker. Dr. Schirmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viz.ai. Dr. Schirmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Microvention. Dr. Schirmer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Werfen. Dr. Schirmer has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for NIH. Dr. Schirmer has stock in NTI. Dr. Schirmer has stock in REIST. The institution of Dr. Schirmer has received research support from NIH. The institution of Dr. Schirmer has received research support from Medtronic. The institution of Dr. Schirmer has received research support from Cerenovus. The institution of Dr. Schirmer has received research support from MIVI. The institution of Dr. Schirmer has received research support from Balt. The institution of Dr. Schirmer has received research support from Microvention. The institution of Dr. Schirmer has received research support from Stryker. The institution of Dr. Schirmer has received research support from Penumbra. The institution of Dr. Schirmer has received research support from NICO. The institution of Dr. Schirmer has received research support from Route 92.
Philipp Hendrix, MD, PhD Dr. Hendrix has nothing to disclose.